
|Articles|December 15, 2002
The Growth Factor
New York-The pharmacologic use of growth factors already FDA approved and useful in treating recalcitrant diabetic leg ulcers shows promise as an off-label therapy for other wounds that heal slowly, Chris Arpey, M.D., associate director of dermatologic surgery, University of Iowa, said.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Global Hidradenitis Suppurativa Atlas (GHiSA) Finds HS Affects 1% of the World's Population
2
Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC
3
Phase 2 Nemolizumab Trial Opens for CPUO
4
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
5


















